• Home
  • About IBT
    • Vision and Mission
    • IBT History
    • Management
    • Board of Directors
    • Advisory Board
  • Pipeline
    • IBP-9414
    • IBP-1016
  • Investors & Media
    • Shares
    • Share Issue
    • Ownership Structure
    • Presentations
    • Corporate Governance
    • Calendar
    • Financial Reports
    • Press Releases
    • News
    • Investors & Media Contact
  • Contact Us
IBT Logo IBT Logo
  • En
  • Sv
  • Home
  • About IBT
    • Vision and Mission
    • IBT History
    • Management
    • Board of Directors
    • Advisory Board
  • Pipeline
    • IBP-9414
    • IBP-1016
  • Investors & Media
    • Shares
    • Share Issue
    • Ownership Structure
    • Presentations
    • Corporate Governance
    • Calendar
    • Financial Reports
    • Press Releases
    • News
    • Investors & Media Contact
  • Contact Us

Press releases


Outcome of Infant Bacterial Therapeutics’ rights issue

 

To access the press release, please read the following disclaimer here.

February 2, 2018

Latest Press releases

Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2020
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2019
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2019
Infant Bacterial Therapeutics has recruited the first patient in the pivotal Phase III clinical study
FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
This site uses cookies – small text-based files that are placed on your device to help us provide a better user experience. Find out more.
Contact | info@ibtherapeutics.com
© Copyright Infant Bacterial Therapeutics AB 2019
Cookie Policy Privacy Policy Terms of Use